Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA approves Merck's letermovir to prevent CMV in kidney transplant recipients
FDA approves Merck's letermovir to prevent CMV in kidney transplant recipients
FDA approves Merck's letermovir to prevent CMV in kidney transplant recipients
Submitted by
admin
on June 6, 2023 - 4:15pm
Source:
Healio
News Tags:
Merck
FDA
letermovir
CMV
kidney transplants
Prevymis
Headline:
FDA approves Merck's letermovir to prevent CMV in kidney transplant recipients
snippet:
Letermovir was first approved in 2017 for high-risk stem cell transplant recipients.
CMV is relatively common in adults but is normally dormant.
Do Not Allow Advertisers to Use My Personal information
